ARK Invest's position in KMDA, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| IZRL | 25,527 | $209K | 0.17% | #68 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-12 | IZRL | Buy | New position | 25,527 | $209K |
| 2026-07-16 | IZRL | Sell | Closed position | 196,137 | $1.4M |
| 2026-07-15 | IZRL | Sell | Trimmed | 67,167 | $483K |
| 2026-04-16 | IZRL | Sell | Trimmed | 6,253 | $52K |
| 2026-01-15 | IZRL | Buy | Added | 247,433 | $2.1M |
| 2026-01-14 | IZRL | Buy | New position | 12,167 | $97K |
| 2025-10-16 | IZRL | Sell | Closed position | 242,103 | $1.6M |
| 2025-10-15 | IZRL | Sell | Trimmed | 20,452 | $137K |
| 2025-07-21 | IZRL | Buy | Added | 7,588 | $60K |
| 2025-04-17 | IZRL | Buy | Added | 230,498 | $1.5M |
| 2025-04-16 | IZRL | Buy | New position | 27,570 | $178K |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for…
See KMDA's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open KMDA on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.